FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1976156924> ?p ?o ?g. }

• W1976156924 endingPage "2642" @default.
• W1976156924 startingPage "2633" @default.
• W1976156924 abstract "This phase III study investigated the addition of aflibercept to gemcitabine, in patients with advanced pancreatic cancer.Patients with metastatic pancreatic cancer were randomly assigned to receive either intravenous (i.v.) aflibercept, 4 mg/kg every 2 weeks, or matching placebo combined with gemcitabine, 1000 mg/m(2) i.v. weekly for 7 weeks out of 8, then weekly for 3 weeks out of 4 until progressive disease, unacceptable toxicity or withdrawal of consent. The primary objective was to demonstrate an improvement in overall survival (OS) between the treatment arms.The study was stopped for futility following a planned interim analysis of OS in 427 randomised patients. With a median follow-up of 7.9 months, based on the 546 patients at study termination, median OS was 7.8 months in the gemcitabine plus placebo arm (n=275) versus 6.5 months in the gemcitabine plus aflibercept arm (n=271), which was not significant (hazard ratio 1.165, 95% confidence interval (CI) 0.921-1.473, p=0.2034). Median progression-free survival was 3.7 months in both arms. Treatment discontinuations due to adverse events were more frequent in the aflibercept than in the placebo-containing arm (23% versus 12%).Adding aflibercept to gemcitabine did not improve OS in patients with metastatic pancreatic cancer." @default.
• W1976156924 created "2016-06-24" @default.
• W1976156924 creator A5011817630 @default.
• W1976156924 creator A5012446712 @default.
• W1976156924 creator A5012509989 @default.
• W1976156924 creator A5012784092 @default.
• W1976156924 creator A5013626155 @default.
• W1976156924 creator A5015917994 @default.
• W1976156924 creator A5030556396 @default.
• W1976156924 creator A5077135387 @default.
• W1976156924 creator A5082045927 @default.
• W1976156924 creator A5090083240 @default.
• W1976156924 date "2013-08-01" @default.
• W1976156924 modified "2023-10-14" @default.
• W1976156924 title "Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer" @default.
• W1976156924 cites W1931508686 @default.
• W1976156924 cites W1965402114 @default.
• W1976156924 cites W1980725734 @default.
• W1976156924 cites W1981989535 @default.
• W1976156924 cites W2012424898 @default.
• W1976156924 cites W2014366767 @default.
• W1976156924 cites W2064926421 @default.
• W1976156924 cites W2075457174 @default.
• W1976156924 cites W2083452953 @default.
• W1976156924 cites W2097642908 @default.
• W1976156924 cites W2105669313 @default.
• W1976156924 cites W2105677187 @default.
• W1976156924 cites W2115898240 @default.
• W1976156924 cites W2116886408 @default.
• W1976156924 cites W2117105709 @default.
• W1976156924 cites W2123769936 @default.
• W1976156924 cites W2126275851 @default.
• W1976156924 cites W2128095147 @default.
• W1976156924 cites W2131879853 @default.
• W1976156924 cites W2133707964 @default.
• W1976156924 cites W2137508065 @default.
• W1976156924 cites W2144025124 @default.
• W1976156924 cites W2147546342 @default.
• W1976156924 cites W2151253787 @default.
• W1976156924 cites W2154502317 @default.
• W1976156924 cites W2155912767 @default.
• W1976156924 cites W2157769714 @default.
• W1976156924 cites W2158134441 @default.
• W1976156924 cites W2158397794 @default.
• W1976156924 cites W2246182165 @default.
• W1976156924 doi "https://doi.org/10.1016/j.ejca.2013.04.002" @default.
• W1976156924 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23642329" @default.
• W1976156924 hasPublicationYear "2013" @default.
• W1976156924 type Work @default.
• W1976156924 sameAs 1976156924 @default.
• W1976156924 citedByCount "154" @default.
• W1976156924 countsByYear W19761569242013 @default.
• W1976156924 countsByYear W19761569242014 @default.
• W1976156924 countsByYear W19761569242015 @default.
• W1976156924 countsByYear W19761569242016 @default.
• W1976156924 countsByYear W19761569242017 @default.
• W1976156924 countsByYear W19761569242018 @default.
• W1976156924 countsByYear W19761569242019 @default.
• W1976156924 countsByYear W19761569242020 @default.
• W1976156924 countsByYear W19761569242021 @default.
• W1976156924 countsByYear W19761569242022 @default.
• W1976156924 countsByYear W19761569242023 @default.
• W1976156924 crossrefType "journal-article" @default.
• W1976156924 hasAuthorship W1976156924A5011817630 @default.
• W1976156924 hasAuthorship W1976156924A5012446712 @default.
• W1976156924 hasAuthorship W1976156924A5012509989 @default.
• W1976156924 hasAuthorship W1976156924A5012784092 @default.
• W1976156924 hasAuthorship W1976156924A5013626155 @default.
• W1976156924 hasAuthorship W1976156924A5015917994 @default.
• W1976156924 hasAuthorship W1976156924A5030556396 @default.
• W1976156924 hasAuthorship W1976156924A5077135387 @default.
• W1976156924 hasAuthorship W1976156924A5082045927 @default.
• W1976156924 hasAuthorship W1976156924A5090083240 @default.
• W1976156924 hasConcept C121608353 @default.
• W1976156924 hasConcept C126322002 @default.
• W1976156924 hasConcept C141071460 @default.
• W1976156924 hasConcept C142724271 @default.
• W1976156924 hasConcept C143998085 @default.
• W1976156924 hasConcept C168563851 @default.
• W1976156924 hasConcept C204787440 @default.
• W1976156924 hasConcept C207103383 @default.
• W1976156924 hasConcept C27081682 @default.
• W1976156924 hasConcept C2776694085 @default.
• W1976156924 hasConcept C2777802072 @default.
• W1976156924 hasConcept C2778749236 @default.
• W1976156924 hasConcept C2780210213 @default.
• W1976156924 hasConcept C2780258809 @default.
• W1976156924 hasConcept C44249647 @default.
• W1976156924 hasConcept C61943457 @default.
• W1976156924 hasConcept C71924100 @default.
• W1976156924 hasConcept C90924648 @default.
• W1976156924 hasConceptScore W1976156924C121608353 @default.
• W1976156924 hasConceptScore W1976156924C126322002 @default.
• W1976156924 hasConceptScore W1976156924C141071460 @default.
• W1976156924 hasConceptScore W1976156924C142724271 @default.
• W1976156924 hasConceptScore W1976156924C143998085 @default.
• W1976156924 hasConceptScore W1976156924C168563851 @default.
• W1976156924 hasConceptScore W1976156924C204787440 @default.

• next